MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism
Ontology highlight
ABSTRACT: The p53 inhibitor MDMX is overexpressed in the vast majority of patients with acute myeloid leukemia (AML). Utilizing hematopoietic stem cells from four non-leukemic/pre-leukemic murine models, we performed bulk transcriptomic analysis to evaluate the impact of Mdmx overexpression.
ORGANISM(S): Mus musculus
PROVIDER: GSE164838 | GEO | 2021/01/14
REPOSITORIES: GEO
ACCESS DATA